Among HER2-positive oesophago-gastric cancer patients treated with first-line standard-of-care trastuzumab-based chemotherapy, response rates were 47% and median overall survival (OS) was 13.8 months in the landmark phase 3 ToGA trial (4). This evidence concerns the gene ERBB2 and gastric cancer.